Current status of nanomedicine in the chemotherapy of breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current status of nanomedicine in the chemotherapy of breast cancer
Authors
Keywords
Breast cancer, Chemotherapy, Doxorubicin, Micelles, Liposomes, Paclitaxel
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-31
DOI
10.1007/s00280-019-03910-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells
- (2019) Zar Chi Soe et al. Pharmaceutics
- Clinical Trials of Thermosensitive Nanomaterials: An Overview
- (2019) Stefania Nardecchia et al. Nanomaterials
- A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
- (2019) Yasuhiro Fujiwara et al. BRITISH JOURNAL OF CANCER
- Advances in Targeted Therapies for Triple-Negative Breast Cancer
- (2019) Kelly E. McCann et al. DRUGS
- Characteristics, Properties and Analytical Methods of Paclitaxel: A Review
- (2018) Renata Carolina Alves et al. CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY
- Challenges and opportunities from basic cancer biology for nanomedicine for targeted drug delivery
- (2018) Xiaodong Xie et al. CURRENT CANCER DRUG TARGETS
- Stimuli-responsive polymeric micelles for drug delivery and cancer therapy
- (2018) Qing Zhou et al. International Journal of Nanomedicine
- Current development in the formulations of non-injection administration of paclitaxel
- (2018) Xiyou Du et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications
- (2018) Javed Iqbal et al. BIOMEDICINE & PHARMACOTHERAPY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.
- (2018) Erik Hugger Jakobsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
- (2018) Minjun Dong et al. OncoTargets and Therapy
- Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization
- (2018) K. Laxmi Swetha et al. Drug Delivery and Translational Research
- PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy
- (2018) Huailin Yang et al. BIOMACROMOLECULES
- Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release
- (2018) Tsukasa Chida et al. JOURNAL OF CONTROLLED RELEASE
- Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy
- (2017) Josimar O. Eloy et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer
- (2017) Xiaoqiu Wu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeted multidrug delivery system to overcome chemoresistance in breast cancer
- (2017) Yuan Tang et al. International Journal of Nanomedicine
- Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy
- (2017) Hanh Thuy Nguyen et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Paclitaxel: What has been done and the challenges remain ahead
- (2017) Ezequiel Bernabeu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations
- (2017) Ruijuan Luo et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation
- (2017) Mona Alibolandi et al. JOURNAL OF CONTROLLED RELEASE
- Targeted cancer therapy through antibody fragments-decorated nanomedicines
- (2017) Abbas Alibakhshi et al. JOURNAL OF CONTROLLED RELEASE
- Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells
- (2017) Jaleh Varshosaz et al. JOURNAL OF LIPOSOME RESEARCH
- Nanocarriers in cancer clinical practice: a pharmacokinetic issue
- (2017) Luciana Giodini et al. Nanomedicine-Nanotechnology Biology and Medicine
- Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials
- (2017) Yun Liu et al. Oncotarget
- An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
- (2017) In Hae Park et al. Cancer Research and Treatment
- Liposomal Formulations in Clinical Use: An Updated Review
- (2017) Upendra Bulbake et al. Pharmaceutics
- Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes
- (2017) Mari C. Asensio-López et al. PLoS One
- Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer
- (2016) Dae Hwan Shin et al. ARCHIVES OF PHARMACAL RESEARCH
- A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle
- (2016) Howard A. Burris et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
- (2016) E. Pham et al. CANCER RESEARCH
- New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
- (2016) Alberto A. Gabizon et al. DRUG RESISTANCE UPDATES
- Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells
- (2016) Kongtong Yu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
- (2016) Hirofumi Mukai et al. INVESTIGATIONAL NEW DRUGS
- Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
- (2016) Michail Ignatiadis et al. PLoS One
- Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
- (2015) Hiroshi Maeda ADVANCED DRUG DELIVERY REVIEWS
- Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index
- (2015) Esther Tahover et al. ANTI-CANCER DRUGS
- Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
- (2015) Miguel J. Gil-Gil et al. BREAST CANCER RESEARCH AND TREATMENT
- Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
- (2015) Ken-ichi Fujita WORLD JOURNAL OF GASTROENTEROLOGY
- A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
- (2014) A. Awada et al. ANNALS OF ONCOLOGY
- Pegylated liposomal doxorubicin in the management of ovarian cancer
- (2014) Nicoletta Staropoli et al. CANCER BIOLOGY & THERAPY
- SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
- (2014) Jianguo Feng et al. CURRENT PHARMACEUTICAL DESIGN
- Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study
- (2014) V. LORUSSO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
- (2014) Jinsun Lee et al. Journal of Breast Cancer
- Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier
- (2014) Conghui Chen et al. JOURNAL OF DRUG TARGETING
- Preparation, Characterization, and Pharmacodynamics of Thermosensitive Liposomes Containing Docetaxel
- (2014) Hui Zhang et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer
- (2014) Colby S. Shemesh et al. PHARMACEUTICAL RESEARCH
- What nanomedicine in the clinic right now really forms nanoparticles?
- (2014) Sonke Svenson Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Paclitaxel Formulations: Challenges and Novel Delivery Options
- (2014) Chetan Nehate et al. Current Drug Delivery
- Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
- (2013) A. A. Ranade et al. ANNALS OF ONCOLOGY
- Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer
- (2013) Marije Slingerland et al. CLINICAL THERAPEUTICS
- Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors
- (2013) Ana Lluch et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer
- (2013) Sebastian Strieth et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
- (2013) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation
- (2013) HONGBO WANG et al. Molecular Medicine Reports
- A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
- (2012) John F. Deeken et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Nanomedicine
- (2012) Frank Caruso et al. CHEMICAL SOCIETY REVIEWS
- Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM
- (2012) Alka Madaan et al. Clinical & Translational Oncology
- Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts
- (2012) Liang Ye et al. FOOD AND CHEMICAL TOXICOLOGY
- Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
- (2012) Christoph Mamot et al. LANCET ONCOLOGY
- Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
- (2011) Janos Szebeni et al. ADVANCED DRUG DELIVERY REVIEWS
- Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
- (2011) D. Rayson et al. ANNALS OF ONCOLOGY
- Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
- (2011) Silvia Dellapasqua et al. BREAST
- Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
- (2011) E. Curtit et al. EUROPEAN JOURNAL OF CANCER
- A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer
- (2011) D. Amadori et al. EUROPEAN JOURNAL OF CANCER
- Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increasedin vivoactivity
- (2011) Jerzy Gubernator Expert Opinion on Drug Delivery
- Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
- (2011) Ronnie TP Poon et al. Future Oncology
- Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study
- (2011) Avijit Hazra et al. INDIAN JOURNAL OF PHARMACOLOGY
- Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
- (2011) Ken Kato et al. INVESTIGATIONAL NEW DRUGS
- Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)
- (2010) M. S. Rosati et al. ANNALS OF ONCOLOGY
- A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
- (2010) M. Venturini et al. BREAST
- Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
- (2010) Rosalba Torrisi et al. Clinical Breast Cancer
- Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation
- (2010) Anshu Yang et al. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
- Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
- (2010) Chris Oerlemans et al. PHARMACEUTICAL RESEARCH
- Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
- (2010) Danbo Yang et al. Cancers
- Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
- (2009) David Rossi et al. ANTI-CANCER DRUGS
- Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
- (2009) T. Numbenjapon et al. CLINICAL CANCER RESEARCH
- A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors
- (2008) Qian Zhang et al. BIOMEDICINE & PHARMACOTHERAPY
- Nine Months to Progression Using Fourth-Line Liposomally Encapsulated Paclitaxel against Hepatocellular Carcinoma
- (2008) Maximilian Christopeit et al. CHEMOTHERAPY
- Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel
- (2008) G. J. Fetterly et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started